Molecular Partners (MOLN) Competitors

Molecular Partners (NASDAQ:MOLN) and Cronos Group (NASDAQ:CRON) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, media sentiment, community ranking, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings.

Does the media refer more to MOLN or CRON?

In the previous week, Molecular Partners had 10 more articles in the media than Cronos Group. MarketBeat recorded 17 mentions for Molecular Partners and 7 mentions for Cronos Group. Cronos Group's average media sentiment score of 0.83 beat Molecular Partners' score of 0.56 indicating that Cronos Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Molecular Partners	3 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Cronos Group	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts rate MOLN or CRON?

Molecular Partners currently has a consensus price target of $12.00, suggesting a potential upside of 160.02%. Cronos Group has a consensus price target of $3.00, suggesting a potential upside of 57.89%. Given Molecular Partners' stronger consensus rating and higher probable upside, research analysts clearly believe Molecular Partners is more favorable than Cronos Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Molecular Partners	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.50
Cronos Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Which has more risk & volatility, MOLN or CRON?

Molecular Partners has a beta of 1.06, suggesting that its stock price is 6% more volatile than the S&P 500. Comparatively, Cronos Group has a beta of 0.89, suggesting that its stock price is 11% less volatile than the S&P 500.

Is MOLN or CRON more profitable?

Cronos Group has a net margin of -42.65% compared to Molecular Partners' net margin of -1,043.01%. Cronos Group's return on equity of -2.56% beat Molecular Partners' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Molecular Partners	-1,043.01%	-39.31%	-35.46%
Cronos Group	-42.65%	-2.56%	-2.47%

Which has stronger valuation & earnings, MOLN or CRON?

Molecular Partners has higher earnings, but lower revenue than Cronos Group. Molecular Partners is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Molecular Partners	$4.97M	37.48	-$69.04M	-$1.81	-2.55
Cronos Group	$117.62M	6.18	-$73.96M	$0.10	19.00

Do insiders & institutionals believe in MOLN or CRON?

26.5% of Molecular Partners shares are held by institutional investors. Comparatively, 8.7% of Cronos Group shares are held by institutional investors. 5.9% of Molecular Partners shares are held by company insiders. Comparatively, 6.9% of Cronos Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Does the MarketBeat Community favor MOLN or CRON?

Cronos Group received 451 more outperform votes than Molecular Partners when rated by MarketBeat users. Likewise, 61.13% of users gave Cronos Group an outperform vote while only 48.15% of users gave Molecular Partners an outperform vote.

Company	Underperform	Outperform
Molecular Partners	Outperform Votes 13 48.15%	Underperform Votes 14 51.85%
Cronos Group	Outperform Votes 464 61.13%	Underperform Votes 295 38.87%

Summary

Molecular Partners beats Cronos Group on 10 of the 19 factors compared between the two stocks.